Similar Articles
801 Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis
802 Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study
803 Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma
804 Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization
805 Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
806 Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models
807 Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions
808 Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma
809 Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma
810 Intravoxel incoherent motion diffusion-weighted magnetic resonance imaging for predicting histological grade of hepatocellular carcinoma: Comparison with conventional diffusion-weighted imaging
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA